Medicinal Products

3359. Deputy Robert O'Donoghue asked the Minister for Health to provide a clear timeline for the conclusion of the reimbursement process for skyclarys given that more than 80 Parliamentary Questions have already been raised on this matter without any indication of when a decision may be reached; and if she will make a statement on the matter. [27038/26]

3366. Deputy Willie O'Dea asked the Minister for Health when the drug sando-K will be available on the medical card for a person (details supplied); and if she will make a statement on the matter. [27087/26]

462. Deputy Pádraig Rice asked the Minister for Health to provide a list of ICS–formoterol combination inhalers currently reimbursed under the general medical services (GMS) scheme, including whether they are approved for use as maintenance and reliever therapy (MART); and if she will make a statement on the matter. [23298/26]

463. Deputy Pádraig Rice asked the Minister for Health to estimate the annual cost to the State of extending reimbursement to provide ICS–formoterol combination inhalers, used as maintenance and reliever therapy (MART), to all children aged 12 to 17 years-of-age diagnosed with asthma; and if she will make a statement on the matter. [23299/26]

473. Deputy Albert Dolan asked the Minister for Health the number of schools currently registered under the Medicines for Listed Organisations framework to hold emergency medicines such as adrenaline auto-injectors for the treatment of severe allergic reactions; and if she will make a statement on the matter. [23373/26]

479. Deputy Danny Healy-Rae asked the Minister for Health if prescription medications are covered on the medical card and drugs refund scheme (details supplied); and if she will make a statement on the matter. [23415/26]

315. Deputy Richard Boyd Barrett asked the Minister for Health if she is aware of the cohort of women who are unable to take HRT due to a history of breast cancer, but for whom the drug veoza provides essential relief from vasomotor symptoms associated with menopause; if she will consider the inclusion of veoza in the drug payment scheme (DPS) as some women are being forced to abandon its usage gi…

321. Deputy Jen Cummins asked the Minister for Health the specific steps are being taken to ensure the HSE recognises the “time-critical” nature of Friedreich’s ataxia during the current price negotiations for skyclarys; and if she will make a statement on the matter. [22549/26]

366. Deputy Máire Devine asked the Minister for Health the status of her Department's plans regarding reimbursement of a medication for a rare, progressive neurological condition (details supplied); and if she will make a statement on the matter. [22734/26]

367. Deputy Máire Devine asked the Minister for Health the steps being taken to ensure the HSE recognises the time-critical nature of Friedrich's Ataxia during current price negotiations with a prescription drug manufacturer. [22735/26]

413. Deputy Barry Ward asked the Minister for Health if her attention has been drawn to calls to allow for the provision of veoza (fezolinetant) under the drug payment scheme; and if she will make a statement on the matter. [22853/26]

414. Deputy Barry Ward asked the Minister for Health the research carried out by her Department into the benefits of the use of veoza (fezolinetant) in the treatment of cancer patients; and if she will make a statement on the matter. [22854/26]

415. Deputy Barry Ward asked the Minister for Health the position regarding any engagement she has had with the HSE in relation to the proposal to allow for the provision of veoza (fezolinetant) under the drug payment scheme; and if she will make a statement on the matter. [22855/26]

416. Deputy Barry Ward asked the Minister for Health the position regarding any engagement she has had with an organisation (details supplied) or any other health group in relation to the proposal to allow for the provision of veoza (fezolinetant) under the drug payment scheme; and if she will make a statement on the matter. [22856/26]

436. Deputy Mark Ward asked the Minister for Health will consider running a pilot orphan drug early-access programme in order that children with Duchenne muscular dystrophy can access givinostat; if a pricing and reimbursement application has been received by the HSE for givinostat; and if she will make a statement on the matter. [23049/26]

437. Deputy Mark Ward asked the Minister for Health if givinostat will be made available for children with Duchenne muscular dystrophy; and if she will make a statement on the matter. [23050/26]

889. Deputy Michael Collins asked the Minister for Health if she will intervene to ensure the HSE prioritises a conclusion to the reimbursement negotiations for skyclarys, given it is the only available treatment for Friedreich’s ataxia and the unmet clinical need recognised in the national rare disease strategy 2025–2030; and if she will make a statement on the matter. [21668/26]

890. Deputy Michael Collins asked the Minister for Health her views on whether current delays in providing skyclarys are compatible with the commitment to “equitable access” outlined in the new National Rare Disease Strategy, particularly when patients across Europe already have access to this therapy; and if she will make a statement on the matter. [21669/26]

931. Deputy Paul Murphy asked the Minister for Health the specific steps being taken to ensure the HSE considers the time-critical nature of Friedreich’s ataxia during the current price negotiations for skyclarys; and the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) are being applied …

970. Deputy Jennifer Whitmore asked the Minister for Health whether she will consider funding the medication skyclarys for people living with Friedreich’s ataxia; and if she will make a statement on the matter. [22147/26]

992. Deputy Joe Cooney asked the Minister for Health further to Parliamentary Question No. 945 of 3 March 2026, for an indicative timeline for when a decision on a case (details supplied) is expected; confirmation of what stage of the review process the application is currently at; whether any interim supports or exceptional access arrangements may be available for patients currently prescribed th…

994. Deputy Conor D. McGuinness asked the Minister for Health if holders of a long-term illness card are entitled to receive blister packs (medication compliance aids) free of charge where they are clinically required; if this entitlement is provided for under the long-term illness scheme or other community drug schemes; the guidance that has been issued by the HSE to pharmacies in this regard; an…

997. Deputy Marie Sherlock asked the Minister for Health when the HSE will make a decision on the reimbursement of a medication (details supplied); and if she will make a statement on the matter. [22282/26]

1032. Deputy Naoise Ó Muirí asked the Minister for Health if she will intervene to ensure that the HSE prioritises the conclusion of reimbursement negotiations for skyclarys, given that it is currently the only available treatment for Friedreich’s ataxia and is identified as addressing an unmet need under the National Rare Disease Strategy 2025–2030; and if she will make a statement on the matter.…

512. Deputy John Clendennen asked the Minister for Health for an update on the accessibility of the drug Givinostat (brand name Duvyzat) for the treatment of Duchenne muscular dystrophy, given the outcome of the NCPE assessment as of 3 March 2026; and if she will make a statement on the matter. [21310/26]